

This material is an English translation of the press release announced on August 29, 2016 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

August 29, 2016

**Notification of the results of the Phase II / III clinical study of HP-3150 in Japan for  
“cancer pain”(an analgesic transdermal drug containing NSAIDs)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces the results of the Phase II / III clinical study for “cancer pain” in Japan for an analgesic transdermal patch containing NSAIDs(Development code: HP-3150, hereinafter referred to as “the product”).

In the Phase II / III clinical study, the efficacy and safety of administration of the product were compared with a placebo in patients suffering from cancer pain. However, expected results were not obtained with respect to efficacy.

We will examine whether or not to continue development by the enforcement of the additional examination on the basis of subsequent thorough investigation of the results obtained from this study.